(Reuters) - GlaxoSmithKline Plc is concluding "feasibility" studies to see if its vaccine technology might be suitable for the Zika virus, a company spokeswoman told Reuters.
http://ift.tt/1njzxgo
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire